Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials (2016 - 2025)

Historic Raw Materials for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $32.8 million.

  • Heron Therapeutics' Raw Materials rose 5746.12% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 5746.12%. This contributed to the annual value of $19.7 million for FY2024, which is 1184.61% up from last year.
  • Per Heron Therapeutics' latest filing, its Raw Materials stood at $32.8 million for Q3 2025, which was up 5746.12% from $35.8 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Raw Materials registered a high of $35.8 million during Q2 2025, and its lowest value of $15.1 million during Q4 2022.
  • For the 5-year period, Heron Therapeutics' Raw Materials averaged around $21.0 million, with its median value being $19.7 million (2024).
  • Its Raw Materials has fluctuated over the past 5 years, first crashed by 3602.48% in 2023, then skyrocketed by 8279.58% in 2025.
  • Over the past 5 years, Heron Therapeutics' Raw Materials (Quarter) stood at $21.2 million in 2021, then decreased by 28.58% to $15.1 million in 2022, then rose by 16.56% to $17.6 million in 2023, then grew by 11.85% to $19.7 million in 2024, then soared by 66.14% to $32.8 million in 2025.
  • Its Raw Materials was $32.8 million in Q3 2025, compared to $35.8 million in Q2 2025 and $19.5 million in Q1 2025.